Sunflower Therapeutics – a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications – announced the oversubscription of a $3 million Simple Agreement for Future Equity (SAFE), which validates ongoing support for the company’s commercial goals.
This oversubscription offers the necessary runway to support the continued launch of Sunflower’s innovative Daisy Petal and Dahlia Petal perfusion fermentation systems. And these systems exemplify the company’s continuous manufacturing equipment, which boasts space-time yield benefits five to ten times greater for diverse proteins than traditional fed-batch methods.
This approach enhances efficiency and promotes sustainability, making it a compelling choice for biopharma, Developing Country Vaccine Manufacturers (DCVM), and the alternative protein sector.
Sunflower is prepared to sell equipment to biomanufacturers globally, supporting product development with thoughtful and resourceful services. As shown by the recent partnership with SK bioscience, this financing enhances awareness of Sunflower’s equipment and service capabilities and highlights their strategic entry into the alternative protein sector with organizations and companies like Clear Current Capital’s support.
This will expand Sunflower’s products into new markets like alternative foods and bioindustrial segments.
KEY QUOTES:
“We are thrilled to have secured the $3M SAFE. These investments highlight the importance of our mission and will empower us to bring our innovative equipment to market, strengthening our capabilities and expanding our presence in the alternative protein sector.”
- Dr. Kerry R. Love, CEO of Sunflower Therapeutics
“There is no path to commercial viability for commodity food ingredients made through precision fermentation without major innovation around the bioprocess. Sunflower’s proprietary continuous fermentation offerings not only allow for a major reduction in CAPEX and OPEX for operators in the space, but the automation it provides can also unlock decentralized production globally, further accelerating progress in the bioeconomy.”
- Steve Molino, Partner & Head of Investments at Clear Current Capital
